10th Dresden Symposium on Autoantibodies
Dresden, September 22–25, 2011

Final Programme
The modern Lecture Hall Centre of the Technical University of Dresden, venue since the 6th Dresden Symposium on Autoantibodies, 2002
Dear Colleagues,

On behalf of the Organizing Committee it is a great pleasure to welcome you to our jubilee event, the 10th Dresden Symposium on Autoantibodies. The Symposium is organised by the Institute of Immunology of the Medical Faculty of the Technical University Dresden in cooperation with the Association for the Advancement of Immune Diagnostics (www.gfid-ev.de) and the Section Immunodiagnostic of the German Society for Clinical Chemistry and Laboratory Medicine (www.dgkl.de). The goal is to bring together clinicians and scientists specialising in "autoimmunology" to exchange academic information and to present and discuss the results of basic and applied research on autoantigens, autoantibodies and autoimmunity.

The current symposium entitled “From Prediction to Prevention of Autoimmune Diseases” will focus on different aspects of the pathogenesis, the prediction, novel treatment regimes and prevention of systemic and organ specific autoimmune diseases as well as autoimmune graft rejections. For this, also rare autoimmunopathies such as autoimmune forms of thrombotic microangiopathies, nephropathies, myopathies and cardiomyopathies will be discussed. Furthermore, it is a tradition of the Dresden meetings to speak about methodological aspects of autoantibody determinations as well as about diagnostic strategies for autoimmune diseases.

The goal of prediction of autoimmune diseases is prevention and/or early intervention to avert morbidity and mortality. Often the formation of autoantibodies precedes the clinical manifestations. This may provide a therapeutic window of opportunity to reverse the autoimmune process. However, large prospective studies are required to evaluate the risk of disease development in autoantibody positive persons. In type 1 diabetes autoantibody detection enables the identification of patients with increased risk of developing the disease. A similar development is expected for rheumatoid arthritis. Therefore, both diseases may serve as models for prevention and novel treatment strategies. A prerequisite for prevention and curative therapy is the very early or even predictive diagnosis by biomarker analyses. The improvement, optimization and standardization of autoantibody determination as well as evaluation studies are essential in this process. We expect that this 10th anniversary meeting on autoantibodies will stimulate all kind of activities regarding prediction and prevention of autoimmune diseases.

We would like to express our thanks to the members of the International Advisory Board and to the active contributors who will present their latest achievements as well as to the many sponsors who enabled this symposium. We expect that our 10th Dresden Symposium on Autoantibodies will stimulate a broad debate how the new achievements from the bench work could help to improve diagnostics and therapy of autoimmune diseases. We hope that you will enjoy the scientific programme and your stay in Dresden.

Karsten Conrad
On behalf of the Organizing Committee
A SHORT HISTORY OF DRESDEN SYMPOSIA ON AUTOANTIBODIES

Our anniversary event is the occasion for a short reminiscence: Two decades ago, in 1990, we realized the First Dresden Symposium on Autoantibodies, just one week after the reunification of Germany. Clinicians and scientists from the Eastern and the Western part of Germany, Austria and Luxembourg discussed mainly methodical aspects of autoantibody determinations but also the clinical and pathogenic relevance of autoantibodies. The topics of the Second Symposium in April 1993 dealt mainly with diagnostic aspects. The Third Symposium in September 1996 was a turning point in such a way that we realized the first international meeting with participants from 14 countries. The series of international symposia was not possible without the active help of the co-chairs and members of the international advisory committee as well as the members of the national organizing committee. It was a happenstance that the support of three international opinion leaders in the field of autoantibody research, René Luis Humbel (Luxembourg), Eng M. Tan (La Jolla, USA) and Yehuda Shoenfeld (Tel-Hashomer, Israel) led to the successful start and continuation of our international symposia since 1996. Equally, the other co-chairs of the following symposia, Michael Meurer (Dresden, Germany), Marvin Fritzler (Calgary, Canada), Michael Bachmann (Dresden, Germany), Edward K. L. Chan (Gainesville, USA), Allan Wiik (Copenhagen, Denmark) and Philipp von Landenberg (Olten, Switzerland), had a key role in the organization and in the success of these meetings.


Topics and Speakers
The main purpose of the Dresden Symposia is to provide a podium for clinicians and scientists specialized in "autoimmunology" to exchange academic information and to present and discuss the results of basic and applied research on autoantigens, autoantibodies and
autoimmunity. Besides methodical aspects of autoantibody determinations and diagnostic strategies for autoimmune diseases the autoantibody symposia focused on various aspects of the induction, pathogenicity and clinical relevance of autoantibodies. Furthermore, each symposium had its own main focus: Pathogenic idiotypes, silica exposure and autoimmunity (3rd Symposium, 1996); autoantibodies and tumors (4th Symposium, 1998); autoantigens – structure, function and role in the pathogenesis of autoimmune diseases (5th Symposium, 2000); the impact of genomics/ribonomics/proteomics on autoantigen and autoantibody research, autoantibodies against receptor structures, pathogenesis and therapy of anti-receptor-antibody induced diseases, autoantibodies and epidemiology (6th Symposium, 2002); animal models, natural autoantibodies, molecular mechanisms of xenobiotic-induced autoimmunity, therapy-induced antibodies (7th Symposium, 2004); prediction and early diagnosis of autoimmune diseases (8th Symposium, 2007); the spectrum and pathogenesis of noninfectious inflammatory and sclerosing diseases, the role of epigenetics and innate immunity in the pathogenesis of autoimmune diseases, biological therapy of autoimmune diseases (9th Symposium, 2009). During the symposia the development of important novel diagnostic options (e.g., autoantibodies against tissue transglutaminase, citrullinated proteins/peptides, gangliosides, ion channel and receptor proteins) and methods (e.g., multiplex assays) have been well documented.

Up to now, clinicians and scientists from 44 countries, mainly from Europe and North America, but also from South America, Asia, Australia, New Zealand and North Africa, attended the symposia to present and/or discuss various aspects of the etiopathogenesis, diagnostics and therapy of autoimmune diseases. Among these participants were many young scientists but also pioneers of autoimmunity research. So we are very proud that we could welcome Noel R. Rose, Baltimore, USA (Witebsky-Rose criteria; research on autoimmune thyroid diseases and pathomechanism of autoimmune diseases), Eng M. Tan, La
Jolla, USA (1966: discovery of Sm antibodies together with H.G. Kunkel; research on auto-
tibodies against extractable nuclear antigens among others), Morris Reichlin, Oklahoma
City, USA (discovery and research on Ro and La antibodies), Walther van Venrooij,
Nijmegen, The Netherlands (autoantibodies against citrullinated proteins/peptides) and
Angela Vincent, Oxford, UK (ion channel antibodies) to one or more of our symposia.
Equally, we highly appreciate the contributions off all experts, who presented their newest
data during the symposia and who are named in the programs of the past symposia publis-
hed on www.gfid-ev.de.

Co-Chairs since the 6th and 7th Dresden Symposium on Autoantibodies, respectively. Left: Marvin J.
Fritzler talking at the 8th Dresden Symposium on Autoantibodies 2007. Right: Edward K.L. Chan in
discussion with Henri-André Ménard at the 9th Symposium 2009.

Organisation and Sponsoring
The organisatory aspects including cultural programmes of the symposia were performed
by Blackwell GCM, Berlin, Germany (1996), Porstmann Kongresse GmbH, Berlin,
Germany (1998), P & R Kongress GmbH, Berlin, Germany (2000), and since 2004 by the
Association for the Advancement of Immune Diagnostics, Dresden, Germany (founded
during the 6th Symposium in 2002). Up to now, more than 50 companies have participa-
ted in the industrial exhibitions, among them some that are not existing yet and others that
were founded in the past years. Representatively, we would like to mention the following
companies which were present four times or more often at the Dresden symposia:
BioSystems S.A., Barcelona, Spain (4 times); DLD Diagnostika GmbH, Hamburg, Germany
(6); Herrmann-Biermann/DPC Biermann GmbH, Bad Nauheim, Germany (4);
Elias/Pharmacia diagnostics/Phadia GmbH, Freiburg, Germany (6); Hiss Diagnostics
GmbH, Freiburg, Germany (4); Mast Diagnostica Laboratoriumspräparate GmbH,
Rheinfeld, Germany (4); IMTEC/HUMAN GmbH, Berlin/Wiesbaden, Germany (7);
Medipan GmbH, Dahlewitz, Germany (5); ORGENTEC Diagnostika GmbH, Mainz,
Germany (7); The Binding Site GmbH, Schwetzingen, Germany (7); Viramed Biotech AG,
Planegg, Germany (4); and EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany (8). Furthermore, the Dresden meetings were partially sponsored by the DFG Deutsche Forschungsgemeinschaft (Bonn, Germany) and the Medical Faculty of the Technical University Dresden (Dresden, Germany). Herewith we thank all sponsors that contributed essentially to the success of the past symposia.

Dresden Prize on the Study of Autoantibodies
The Dresden Prize on the Study of Autoantibodies was founded by the Association for the Advancement of Immune Diagnostics to award young scientists up to age 35 for their contribution of outstanding results on the research on autoantibodies presented at the Dresden Symposia on Autoantibodies. The prize of 1000 EUR was awarded for the first time in 2004 at the 7th Dresden Symposium on Autoantibodies to Nikolina Mihailova & Elisaveta Voynova from the Bulgarian Academy of Sciences, Sofia (Bulgaria). They presented their results on the „Selective suppression of DNA-specific B cells in lupus mice“.

The second winner at the 8th Symposium (2007) was Joyce van Beers from the Radboud University Nijmegen (The Netherlands) with her results on „The synovial citrullinome of rheumatoid arthritis patients“. Her proteomics analyses provided an inventory of synovial proteins in the inflamed joints of rheumatoid arthritis (RA) patients. Novel citrullinated proteins that may be targeted by the immune system in the synovia of RA patients were identified in synovial fluid samples of RA patients. The winner of the 9th Symposium (2009), Klaartje Somers from the Hasselt University Diepenbeek (Belgium), presented her observations on „Novel autoantibody targets in multiple sclerosis and rheumatoid arthritis“. By using a cDNA phage display approach, Klaartje Somers et al. identified novel autoantigenic targets of autoantibodies in patients with multiple sclerosis and rheumatoid arthritis (RA). Novel RA-specific autoantibodies that are also present in rheumatoid factor and anti-CCP negative patients with early RA may help to improve early diagnosis, prediction and subtyping of RA.
Congress books and Autoantibody Guides

Since the 4th meeting (1998) special congress books comprising review articles as well as abstracts of the active participants were published at time of the Dresden Symposia. We have to thank all authors, especially those who presented reviews of highly interesting topics that were also discussed during the meeting. The title of the first congress report was „Pathogenic and diagnostic relevance of autoantibodies“ (Pabst Science Publishers, Lengerich 1998). In the following, a special book series termed „Autoimmunity, autoantigens, autoantibodies (AAA)“ was introduced that includes also Autoantibody Guides presented at the symposia:


Cultural events

Each scientific meeting was accompanied by a special event regarding culture and traditions of Dresden and Surroundings. The Social Dinner of the 3rd Symposium (the first international one) took place in the historical restaurant „Italienisches Dörfchen“ on the Theatre Square, situated between the Semper Opera House, the river Elbe, the Zwinger Museum and the Court Church. At the 4th Symposium we visited „Pfunds Molkerei“, the most beautiful milk shop of the world (since 1998 in the Guinness Book of Records). The cultural highlight of the 5th Symposium was the visit of the specialized restaurant „Silberstollen“ dedicated to the traditions of mining in Saxony (unfortunately closed since the great flood in 2002). Moritzburg Castle, the hunting lodge and summer residence of August the Strong (1670-1733) near Dresden was the event location of the 6th Symposium. Before the Social Dinner, a guided tour through the baroque museum provided an insight into the largest collection of ornamental leather tapestries in the world, Saxon and French furniture, Oriental and Meissen porcelain, paintings of the 17th and 18th century and the most important collection of hunting trophies in Europe. A guided tour to the Pillnitz Palace and Park and
Social Dinner in the historical Orangery of the Pillnitz Palace highlighted the cultural part of the 7th Symposium. Pillnitz Castle, the former summer residence of the Saxon royal court is today the home of the Museum of Decorative Arts. The park deserves closer attention as it combines the strict forms of the baroque period with those of an English landscape garden. Alongside many rare trees the over 200-year-old Japanese camellia is a particular magnet for visitors.

Dancing with countess Cosel at Pillnitz Park.

A Guided tour and Social Dinner in the Meissen Castle were the cultural highlights of the 8th Dresden Symposium. The establishment of the Meissen Castle goes back to the year 929. In 1470, the brilliant master-builder Arnold von Westfalen created a late gothic castle complex, the first palatial castle of its kind in German building history. Between 1710 and 1863, the castle was the first domicile of the famous Meissen porcelain factory.

Social Dinner at Meissen Castle.
During the 9th Dresden Symposium we organised a guided visit and Social Dinner in the Castle of Weesenstein. Weesenstein Castle in the Müglitz valley is one of the most beautiful tourist destinations in the surroundings of Dresden. The 700-year-old castle on a rock above the village presents its visitors saxon history from the Middle Ages through to the 19th century. Especially delightful is a walk in the castle gardens.

Social Dinner at Weesenstein Castle.

In the next years we will attempt to continue the successful series of Dresden Symposia on Autoantibodies and we hope to welcome you again at the 11th Dresden Symposium on Autoantibodies in September of 2013.
Registration

Welcome and Introduction

FROM PREDICTION TO PREVENTION OF AUTOIMMUNE DISEASES
Co-Chairs: K. Conrad (Dresden, Germany)  
M.J. Fritzler (Calgary, Canada)

From prediction to prevention of autoimmune diseases – current state and perspectives  
*Karsten Conrad (Dresden, Germany)*

The value of autoantibodies for the prediction of autoimmune diseases  
*Yehuda Shoenfeld (Tel Hashomer, Israel)*

Antibody proteases as preclinical diagnostic and predictive tools in monitoring clinical autoimmunity conditions  
*Sergey Suchkov (Moscow, Russia)*

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

PATHOGENESIS AND PREVENTION OF AUTOIMMUNE DISEASES
Co-Chairs: E.K.L. Chan (Gainesville, USA)  
P.L. Meroni (Milan, Italy)

Pathogenesis of APS: understanding the antibodies  
*Pier Luigi Meroni (Milan, Italy)*

On the role of nucleic acids and their binding proteins in the pathogenesis of autoimmune arthritis in rats, mice and men  
*Günter Steiner (Vienna, Austria)*

The role of miRNAs in the regulation of immunological functions and the prevention of autoimmunity  
*Edward K.L. Chan (Gainesville, USA)*
The role of Vitamin D in immunologic homeostasis and prevention of autoimmunity
Nancy Agmon-Levin (Ramat Gan, Israel)

Anti-dsDNA antibody production is restricted by the germline composition of DH genes
A. Silva-Sanchez, C.R. Liu, P. Kapoor, T. Schoeb, H.W. Schroeder (Birmingham, USA)

Prognostic value of antibodies to oxidized low-density lipoprotein in acute coronary syndrome and stable coronary artery disease
Sándor Sipka, R. Laczik, I. Scípö, P. Szodoray, S. Sipka Jr., M. Sokol, P. Soltész (Debrecen, Hungary)

Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with HLA-DRB1 shared epitope alleles
Joyce J.B.C. van Beers, Annemiek Willemze, Rene E.M. Toes, Ger J.M. Pruijn (Nijmegen, The Netherlands)

Welcome Reception
PLENARY LECTURE
Type 1 diabetes: A model for disease prediction and prevention
Matthias G. von Herrath (La Jolla, USA)

AUTOIMMUNE THROMBOTIC MICROANGIOPATHIES
Co-Chairs: M.J. Fritzler (Calgary, Canada)  
P. Zipfel (Jena, Germany)
Thrombotic microangiopathies: Towards a pathogenetically based classification
Peter Zipfel (Jena, Germany)

The anti-factor H autoantibody associated hemolytic uremic syndrome
Marie-Agnés Dragon-Durey (Paris, France)

Atypical hemolytic uremic syndrome-associated anti-factor H autoantibodies inhibit factor H binding to pentraxin 3
Anne Braunschweig, Stefanie Strobel, Mihály Józsi (Jena, Germany)

COFFEE BREAK – POSTER AND EXHIBITION VIEWING
Poster viewing
P1–P20  Rheumatoid arthritis
Contributions of candidates for the Dresden Prize on the Study of Autoantibodies

PERSPECTIVES IN THE TREATMENT OF AUTOIMMUNE DISEASES
Co-Chairs: A. Kromminga (Hamburg, Germany)  
F. Hiepe (Berlin, Germany)

Therapeutic concepts of targeting autoreactive plasma cells
Falk Hiepe (Berlin, Germany)

A decade of peptide based immunotherapy for autoimmune diseases
Miri Blank (Tel-Hashomer, Israel)
FRIDAY
SEPTEMBER 23

11.35–12.00
Aptamer based immunotherapy
Annekathrin Haberland (Berlin, Germany)

12.00–12.15
Attenuation of autoimmunity by anti-human-interleukin-17 aptamer in mouse models
Yoshikazu Nakamura, Hironori Adachi, Akira Ishiguro (Tokyo, Japan)

12.15–12.30
Clinical impact of neutralizing antibodies against TNFα inhibitors
Arno Kromminga (Hamburg, Germany)

12.30–14.00
LUNCH BREAK – POSTER AND EXHIBITION VIEWING
Poster viewing
P21-P45 Systemic and organ specific autoimmune diseases

12.30–14.00
EASI LUNCH MEETING (room 101)
(EASI members only)

14.00–15.20
ASIA SYNDROME AND AUTOIMMUNE GRAFT REJECTION
Co-Chairs: D. Reinhold (Magdeburg, Germany) Y. Shoenfeld (Tel Hashomer, Israel)

14.00–14.20
Autoimmune syndromes induced by adjuvants (ASIA)
Yehuda Shoenfeld (Tel Hashomer, Israel)

14.20–14.40
Induction and role of autoantibodies in early graft rejection
Gavin J. Pettigrew (Cambridge, UK)

14.40–15.00
Alloimmune response-induced autoimmunity:
Role in the pathogenesis of chronic allograft rejection
Thalachallour Mohanakumar (St. Louis, USA)

15.00–15.20
Autoantibodies against G-protein coupled receptors (GPCRs)
Kai Schulze-Forster (Luckenwalde, Germany)

15.20–15.50
COFFEE BREAK - POSTER AND EXHIBITION VIEWING
PRESENTATIONS OF THE CANDIDATES FOR THE DRESDEN PRIZE ON THE STUDY OF AUTOANTIBODIES (in alphabetical order of the presenting authors)

Co-Chairs: K. Conrad (Dresden, Germany) 
U. Sack (Leipzig, Germany)

Role of functional antibodies against vascular receptors in systemic sclerosis
Mike Becker (Berlin, Germany)

Novel autoantibodies to EIF3 in polymyositis
Zoe Betteridge (Bath, UK)

Autoantibodies to cytoplasmic rod/ring structure targeting CTP/GTP synthetic pathway in HCV patients treated with interferon/ribavirin
Wendy C. Carcamo (Gainesville, USA)

Patient derived human monoclonal islet autoantibodies in Type 1 Diabetes
Mara Catani (Dresden, Germany)

Development and optimization of a sensitive peptide ELISA for autoantibody testing in early and seronegative RA
Liesbeth de Winter, Klaartje Somers, Piet Geusens, Dirk Elewaert, Piet Stinissen, Veerle Somers (Diepenbeek, Belgium)

Peripheral and intrathecal immortalized B cells from multiple sclerosis patients show clonal expansion and produce autoreactive antibodies
Judith Fraussen (Diepenbeek, Belgium)

ANA immunofluorescence patterns and their association with reactivity to molecularly defined nuclear targets in children with type 1 autoimmune hepatitis
FRIDAY
SEPTEMBER 23

17.00–17.10 Anti-Neurofascin autoantibodies: Assay development and analysis of inflammatory diseases of the CNS and PNS
Judy King Man Ng (Munich, Germany)

17.10–17.20 Discovery of novel antigenic targets for clinically isolated syndrome
Myrthe Rouwette, Klaartje Somers, C. Govarts, R. Hupperts, B. van Wijmeersch, B. de Jong, M. Verbeek, V. van Pesch, C. Sindic, L. Villar, Piet Stinissen, Veerle Somers (Diepenbeek, Belgium)

17.20–17.30 Autoantibody secreting cells in the nephritic kidneys of lupus prone NZB/W F1 mice are sensitive to bortezomib
Charlotte Starke (Erlangen, Germany)

17.30–18.00 COFFEE BREAK - POSTER AND EXHIBITION VIEWING

18.00–19.30 EASI* -SYMPOSIUM: RHEUMATOID ARTHRITIS
Co-Chairs: M. Haass (Freiburg, Germany)
Y. Shoenfeld (Tel Hashomer, Israel)

18.00–18.20 Value of the ACR Guidelines for the diagnosis pf RA
Manfred Herold (Innsbruck, Austria)

18.20–18.30 RA33 antibodies - new data of a marker linked to CCP negative RA with a mild prognosis
Günter Steiner (Vienna, Austria)

18.30–18.40 CarP antibodies identify RA patients with severe disease progression
Leendert Trouw (Leiden, The Netherlands)

18.40–18.50 Novel autoantibody markers for seronegative rheumatoid arthritis
Veerle Somers (Diepenbeeck, Belgium)

18.50–19.10 Personalized medicine approaches in RA
Marvin Fritzler (Calgary, Canada)

19.10–19.30 Discussion

* European Autoimmunity Standardisation Initiative
PLENARY LECTURE
From prediction to prevention of rheumatoid arthritis
Karina Lundberg (Stockholm, Sweden)

AUTOIMMUNE HEART DISEASES
Co-Chairs: E.K.L. Chan (Gainesville, USA)
G. Steiner (Vienna, Austria)

Dilated cardiomyopathy and myocarditis: Classification, clinical and autoimmune features
Alida L.P. Caforio (Padua, Italy)

Chronic Chagas Heart Disease – From pathogenesis to new treatment regimes
Ingolf Schimke (Berlin, Germany)

Pathophysiology of autoimmune associated congenital heart block: From bench to bedside
Mohamed Boutjdir (New York, USA)

COFFEE BREAK - POSTER AND EXHIBITION VIEWING

NOVEL AUTOANTIBODIES
Co-Chairs: D. Bogdanos (London, UK)
M. Herrmann (Erlangen, Germany)

Novel autoantibodies, clinical phenotypes and pathogenesis of idiopathic myopathies
Zoe E. Betteridge (Bath, UK)

Anti-Mup44: the first inclusion body myositis-specific autoantibody
Helma Pluk, Bazi G. van Engelen, Ger J.M. Pruijn
(Nijmegen, The Netherlands)

Novel autoantibody markers in autoimmune gastrointestinal and liver diseases
Dimitrios P. Bogdanos (London, UK)
### Saturday
#### September 24

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12.15–12.30 | Autoantibodies against galectins as novel biomarkers for the antiphospholipid syndrome.  
  *Martin Hermann (Erlangen, Germany)* |
  *Martin Blüthner, Martin Volkmann, Heribert Appelhans, I. Moosbrugger, C. Wiemann, C. Becker, Hans-Peter Seelig (Karlsruhe, Germany)* |
| 12.40–12.50 | PLA2 receptor antibodies as serological markers of idiopathic membranous nephritis are absent in active membranous lupus nephritis  
  *Iva Gunnarsson, Wolfgang Schlumberger, Johan Rönnelid (Lübeck, Germany)* |
| 12.50–13.00 | Autoantibodies against chaperonin CCT in glomerular immune deposits and sera in patients with membranous nephropathy: possible role in disease progression  
  *Florence Lefeu, Fabienne Fasani, Chantal Jouanneau, Pierre Ronco, Hanna Debiec (Paris, France)* |
| 13.00–14.30 | **LUNCH BREAK – POSTER AND EXHIBITION VIEWING**  
  Poster viewing  
  *P46–P64  Methodical aspects and diagnostic strategies* |
| 12.45–14.30 | **GFID LUNCH MEETING** (room 103)  
  (GFID members only)  
  *DRESDEN PRIZE ON THE STUDY OF AUTOANTIBODIES*  
  Award Ceremony |
| 14.30–15.00 | **COFFEE BREAK - POSTER AND EXHIBITION VIEWING** |
| 15.00–15.30 | **Departure to Königstein**  
  Guided visit of the Königstein Fortress |
| 15.30 | **Social Dinner** |
AUTOANTIBODY DETERMINATIONS – HISTORY AND PERSPECTIVES
Co-Chairs: L. Andrade (Sao Paulo, Brazil)
E. Csernok (Lübeck, Germany)

History of autoimmune serology
René Louis Humbel (Esch-sur-Alzette, Luxembourg)

Autoantibody testing: Current challenges and future opportunities
Marvin Fritzler (Calgary, Canada)

ANCA Testing: Current stage and perspectives
Elena Csernok (Bad Bramstedt, Germany)

COFFEE BREAK – POSTER AND EXHIBITION VIEWING

A RENAISSANCE OF THE HEP-2 CELL ASSAY?
Co-Chairs: R.L. Humbel (Esch-sur-Alzette, Luxembourg)
A. Wiik (Copenhagen, Denmark)

Multicentre collaboration is needed to reach unified classification of IIF ANA and clinical use of strictly defined findings
Allan Wiik (Copenhagen, Denmark)

Distinctive features of autoantibodies in and out the context of overt autoimmunity
Luis E.C. Andrade (Sao Paulo, Brazil)

Determination of non-organ specific autoantibodies by indirect immunofluorescence on HEP-2 cells: Advantages, challenges and perspectives
Rico Hiemann, Nadja Röber, Dirk Roggenbuck, Karsten Conrad (Senftenberg, Germany)

Comparison of an ANA automated reading system with conventional fluorescence microscopy
Thorsten Krieger (Hamburg, Germany)
**SUNNDAY**  
**SEPTEMBER 25**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 12.10-12.20  | Redefining ANA testing: Development of a highly specific ANA HEp-2 test based on immunoabsorption of anti-DFS70 autoantibodies  
*Michael Mahler, Andrea Seaman, Todd Parker, Aaron Llanes, Carol L. Peebles, John G. Hanly, Marvin J. Fritzler (San Diego, USA)* |
| 12.20–12.30  | Automatic reading of ANCA-slides: evaluation of the AKLI-DES system  
*Jan Damoiseaux, Kathleen Mallet, Mia Vaessen, Jos Austen, Jan Willem Cohen Tervaert (Maastricht, The Netherlands)* |
| 12.30–13.30  | LUNCH BREAK – POSTER AND EXHIBITION VIEWING                           |
| 13.30–14.30  | **METHODICAL ASPECTS OF AUTOANTIBODY TESTING**                       |
|              | **Co-Chairs:** T. Krieger (Hamburg, Germany)                        |
|              | M. Mahler (San Diego, USA)                                          |
| 13.30–14.00  | Synthetic peptides as autoantigens in immunoassays                  
*Michael Mahler (San Diego, USA)* |
| 14.00–14.15  | Multiparametric serological testing in autoimmune encephalitis using a recombinant immunofluorescence assay and EUROTIDE technology  
*Klaus-Peter Wandinger, Christine Klingbeil, Patrick Waters, Josep Dalmau, Sandra Saschenbrecker, Kathrin Borowski, Angela Vincent, Christian Probst, Winfried Stöcker (Lübeck, Germany)* |
| 14.15–14.30  | Profiling of antiphospholipid antibodies – Association with cerebrovascular events in antiphospholipid syndrome (APS)  
*Karl Egerer, Dirk Roggenbuck, Thomas Büttner, Barbara Lehmann, Annushka Kohn, Philipp von Landenberg, Eugen Feist, Gerd-Rüdiger Burmester, Thomas Dörner (Berlin, Germany)* |
POSTER EXHIBITION

Poster presentations of candidates for the Dresden Prize on the Study of Autoantibodies (in alphabetical order of the presenting authors)

P1  Role of functional antibodies against vascular receptors in systemic sclerosis

Mike Becker, Angela Kill, Reinmar Undeutsch, Christoph Tabeling, Martin Witzenrath, Wolfgang M. Kuebler, Sebastian Bock, Rudi Samapati, Harald Heidecke, Ivo Lukitsch, Duska Dragun, Gabriela Riemekasten (Berlin, Germany)

P2  Novel autoantibodies to EIF3 in polymyositis

Zoe Betteridge (Bath, UK)

P3  Autoantibodies to cytoplasmic rod/ring structure targeting CTP/GTP synthetic pathway in HCV patients treated with interferon/ribavirin


P4  Patient derived human monoclonal islet autoantibodies in Type 1 Diabetes

Mara Catani, Denise Walther, Stephanie Krause, Michael Christie, Vito Lampasona, Ezio Bonifacio, Anne Eugster (Dresden, Germany)

P5  Anti-vimentin/cardiolipin complex autoantibodies in antiphospholipid syndrome: preliminary data using a new ELISA method

Federica D’Aurizio, M. Fabris, R. Giacomello, J. Peresan, D. Visentini, F. Curcio, E. Tonutti (Udine, Italy)

P6  Assessment of the CTD-screen Phadia-EliA and of the ANA screening assay in the routine clinical laboratory of a general hospital

Milca Geane de Lamos Valim (Sao Paulo, Brazil)

P7  Development and optimization of a sensitive peptide ELISA for autoantibody testing in early and seronegative RA

Liesbeth de Winter, Klaartje Somers, Piet Geusens, Dirk Elewaut, Piet Stinissen, Veerle Somers (Diepenbeek, Belgium)
P8 Multiplex autoantibody detection for serological diagnostics of ANCA associated vasculitis and rapid progressive glomerulonephritis
Kai Großmann, Ilka Knütter, Rico Hiemann, Karsten Conrad, Ulrich Sack, Elena Csernok, Dirk Roggenbuck (Senftenberg, Germany)

P9 Anti-neuronal antibodies in the request context – an annual evaluation of a medical laboratory
Verena Jansen, R. Tripmacher, A. Jagiello, R. Moog, S. Tobisch, R. Lange (Bernau, Germany)

P10 Epstein-Barr virus diffuse early antigen directed immunoglobulin A antibodies in systemic lupus erythematosus
Anette Holck Draborg (Copenhagen, Denmark)

P11 Peripheral and intrathecal immortalized B cells from multiple sclerosis patients show clonal expansion and produce autoreactive antibodies

P12 High frequency immunoadsorption may reduce autoantibodies and improve lung disease in systemic sclerosis (SSc) – lessons from a first case
Nicolai Leuchten, Karsten Conrad, Kerstin Johne, Ulrich Julius, Martin Aringer (Dresden, Germany)

P13 Anti-asialoglycoprotein receptor antibody measured by ELISA is a specific marker of liver autoimmunity and mirrors disease activity in patients with autoimmune hepatitis
Maria G. Mytilinaiou, Dirk Roggenbuck, Tassos Grammatikopoulos, Edward T. Davies, Ourania Romanidou, Eirini I. Rigopoulou, Ian MacFarlane, Giorgina Mieli-Vergani, Diego Vergani, Dimitrios P. Bogdanos (London, UK)

P14 ANA immunofluorescence patterns and their association with reactivity to molecularly defined nuclear targets in children with type 1 autoimmune hepatitis
P15 Anti-Neurofascin autoantibodies: Assay development and analysis of inflammatory diseases of the CNS and PNS
Judie King Man Ng, Joachim Malotka, Naoto Kawakami, Tobias Derfuss, Mohsen Khademi, Tomas Olsson, Philipp Sämann, Frank Weber, Masaaki Odaka, Nobuhiro Yuki, Björn Tackenberg, Johannes Brettschneider, Matthew Rasband, Christopher Linington, Harald Prüss, Jan Schwab, Reinhard Hohlfeld, Hartmut Wekerle, Klaus Dornmair, Edgar Meinl (Munich, Germany)

P16 Identification of linear epitopes of HuD antibodies related to paraneoplastic diseases
Nicole Hartwig Petersen (Copenhagen, Denmark)

P17 A new ELISA test for the detection of the monoclonality of anti-MAG antibodies
Arnaud Quittard-Pinon, Bernhard Mani, Renato Cotti, Jérome Fernandez, Christiane Caudie (Pierre Benite, France)

P18 Discovery of novel antigenic targets for clinically isolated syndrome
Myrthe Rouwette, Klaartje Somers, C. Govarts, R. Hupperts, B. van Wijmeersch, B. de Jong, M. Verbeek, V. van Pesch, C. Sindic, L. Villar, Piet Stinissen, Veerle Somers (Diepenbeek, Belgium)

P19 Early arthritis and biomarker: A proposal of diagnostic profile gender oriented
T. Castagno, M. Nastro, C. Nastro, I. Soriente, P. Amato, Paola Sabatini (Nocera Inferiore, Italy)

P20 Autoantibody secreting cells in the nephritic kidneys of lupus prone NZB/W F1 mice are sensitive to bortezomib
Charlotte Starke, Vilma Urbonaviciute, Silke Fray, Georg Schett, Reinhard E. Voll (Erlangen, Germany)

Systemic Autoimmune Diseases

P21 Rheumatoid Factors after 70 years. Why cannot be still expected standardization of their determination?
Ivo Lochman, V. Novák, A. Kloudová, J. Martinek, H. Tomášková, I. Půtová (Ostrava, Czech Republic)
P22 Evaluation of the Zenit RA for the detection of citrullinated protein antibodies
An-Sofie Decavele (Ghent, Belgium)

P23 Evaluation of the measurement of anti-CCP antibodies by 2 methods: INOVA anti-CCP3 ELISA assay and BioPlex® 2200 Multiplex assay
Raya Harich, Nicole Fabien (Pierre Benite, France)

P24 Rapid progressive ANA-positive myositis – case report
Marten Kayser, Markus Enderlein, Leonore Unger (Dresden, Germany)

P25 Role of agonistic autoantibodies directed to the angiotensin II type 1 and the endothelin-1 type A receptors in systemic sclerosis
Angela Kill, Jeannine Günther, Mike O. Becker, Harald Heidecke, Duska Dragun, Gabriela Riemekasten (Berlin, Germany)

P26 Systemic Sclerosis – agonistic auto-antibodies directed against the angiotensin receptor type 1 and the endothelin receptor type A and their effects on immune cells
Jeannine Günther, J.A. Calatayud Subias, A. Kill, M.O. Becker, G. Riemekasten (Berlin, Germany)

P27 Anti-tubular basement membrane antibodies: A new pathognomonic parameter in the serological diagnosis of systemic sclerosis
Kristin Rentzsch, Anthonina Ott, Wolfgang Meyer, Sandra Saschenbrecker, Wolfgang Schlumberger, Winfried Stöcker (Lübeck, Germany)

P28 Validation of BIO-RAD vasculitis assays for use on the EvolisTM and EvolisTM twin plus microplate systems
Raisa Lerner, Xiaowen Guo, Wendy Vandam, Tony Prestigiacomo (Hercules, USA)

P29 Validation of BIO-RAD vasculitis assays for use on the PhDTM and PhDTM LX IFA/EIA systems
Raisa Lerner, Xiaowen Guo, Wendy Vandam, Tony Prestigiacomo (Hercules, USA)
P30  Performance of a novel chemiluminescence assay for the detection of PR3- and MPO-ANCA: Comparison with ELISA methods
Michael Mahler, Andrea Seaman, Elena Csernok, Renato A. Sinico, Antonella Radice (San Diego, USA)

P31  Diagnostic of latent form of tuberculosis before anti TNF-treatment
Elizabeth Zánová, D. Kozáková, V. Polanová, I. Solovič, J. Rybár, F. Máliš, J. Rovensk (Piešťany, Slovakia)

P32  Oxidized ATP inhibits T cell mediated autoimmunity
Carmen Barthuber, Philipp A. Lang, Karl S. Lang (Düsseldorf, Germany)

P33  Formation of antiphospholipid antibodies and antibodies to Infliximab in anti-TNF-alpha antibody-treated patients with inflammatory bowel diseases
Karín Malíčková, Ivana Janatková, Nadeshda Machková, Dana Durícová, Martin Bortlik, Tomas Zima, Milan Lukás (Prague, Czech Republic)

P34  Long pentraxin PTX3 and autoantibodies production in autoimmune diseases
S. Valaperta, M. Monari, C. Alpini, E. Baldassarre, Francesco Gioia, A. Montanelli (Varese, Italy)

Organ Specific Autoimmune Diseases

P35  Sunset of routine diagnostics for ICA?
Jan Martinek, Ivo Lochman (Ostrava, Czech Republic)

P36  Neurofilament heavy chains and antibodies against them as markers for axonal damage in patients with multiple sclerosis
L. Fialova, A. Bartos, Jana Svarcova, D. Zimova, I. Malbohan (Prague, Czech Republic)

P37  Relationship between neurofilament light chains and antibodies against them in cerebrospinal fluid in patients with multiple sclerosis
Jana Svarcova, L. Fialova, A. Bartos, D. Zimova, I. Malbohan (Prague, Czech Republic)
Thursday, September 22 (16.00) until Sunday, September 25 (13.30)

P38  Isaac’s syndrome – Casuistry  
Vitezslav Novák, J. Junkerová (Prague, Czech Republic)

P39  Autoantibodies to gp2 – A new marker for Crohn’s Disease  

P40  Determination of anti-deamidated gliadin/anti-tissue transglutaminase antibodies in patients with gliadin and anti-cow’s milk antibodies  
Miroslav Hindos, Karin Malickova, Ivana Janatková (Prague, Czech Republic)

P41  Occurrence of anti-alpha-fodrin antibodies in patients with Crohn’s disease  
Gábor Nagy, M. Papp, I. Scípö, Sándor Sipka (Debrecen, Hungary)

P42  Unusual B cells line in inflammatory bowel disease  
Caterina Defendenti, Silvia Grosso, Fabiola Atzeni, Annamaria Croce, Olivia Senesi, Simone Saibeni, Simona Bollani, Piero Luigi Almasio, Savino Bruno and Piercarlo Sarzi Puttini (Milan, Italy)

P43  Relevance of M2 IgG, IgM and IgA antibodies in primary biliary cirrhosis  
Sascha Swiniarski, Reinhild Klein, H. Ohira, T. Ostler (Freiburg, Germany)

P44  Evaluation of the diagnostic performance of an enzyme immunodot blot for the detection of anti-actin autoantibodies in patients with autoimmune hepatitis  
Bernhard Schlüter, J. Schmalhorst, P. Willeke, H. Schotte (Münster, Germany)

P45  Construction and production of synthetic competitors for suppression of the activity of immune complexes causing IgA nephropathy  
Alena Kasperova, Lydie Czernekova, Katerina Zachova, Milada Horynova, Jan Novak, Jiri Mestecky, Ivan Sterzl, Milan Raska (Prague, Czech Republic)
Methodical Aspects and Diagnostic Strategies

P46 Comparative analysis of sera reacting with linear peptides and recombinant proteins
Felix Steinbeck, Nadine Born, Peter Lorenz, Björn Ziems, Johannes Wollbold, Michael Hecker, Michael O. Glocker, Hans-Jürgen Thiesen (Rostock, Germany)

P47 Enhanced Biobanking – a prospective approach for the procurement of human biomaterial for the diagnostic industry
Jörg-M. Holldt, Robert Lange (Berlin, Germany)

P48 Development of an interface connecting the mobile reader system OpTrilyzerâ to HL-7 hospital information systems for the use in autoimmune diagnostics
Dennis Krischok, Andreas Schilke, Volker Plickert, Lutz Melchior, Jörg-M. Holldt, Frauke Adams (Berlin, Germany)

P49 Automated interpretation of antinuclear antibody assessment on Hep2-Cells by standardized algorithms
Karl Egerer, Dirk Roggenbuck, Rico Hiemann, Max-Georg Weyer, Thomas Büttner, Boris Radau, Rosemarie Krause, Barbara Lehmann, Eugen Feist, Gerd-Rüdiger Burmester (Berlin, Germany)

P50 Digital image analysis results show high reproducibility and agreement with human interpretation on HEp-2 cells.
Carol Buchner (San Diego, USA)

P51 Clinical evaluation of EliA CTD Screen in CTD patients and control samples in comparison to ANA immunofluorescence (IIF) on HEp-2 cells
Markku Viander, Marja Hietarinta, Jussi Kantele (Turku, Finland)

P52 Cytoplasmic Ring/Rod autoantibodies in patients undergoing screening for antinuclear antibodies (ANA)
Pierluigi Congedo, C. Defendenti, S. Finazzi, E. Arighi, C. Colzani, F. De Filippi, M. Lotzniker, A. Papa, G. Spinzi, R. Terramocci, N. Terreni (Como, Italy)
P53  Standardized detection of anti-dsDNA antibodies by indirect immunofluorescence – A new age for confirmatory tests in SLE diagnostics
Dirk Roggenbuck, Dirk Reinhold, Rico Hiemann, Ursula Anderer, Thomas Büttner, Karsten Conrad (Dahlewitz, Germany)

P54  Computer-Aided Immunofluorescence Microscopy (CAiFM) in the diagnosis of autoimmune and infectious diseases
Winfried Stöcker, Martin Rateike, Markus Morrin, Jörn Voigt, Kristin Rentzsch, Christopher Krause, Konstantin Ens, Hendrik Fauer, Erhardt Barth, Christian Feirer, Daniel Wuttig, Kai Fechner, Steffen Kloth, Thomas Martinetz (Lübeck, Germany)

P55  Performance of the automated immunofluorescence system AKLIDES® for detection of antineutrophil cytoplasmic antibodies
Ilka Knütter, Rico Hiemann, Therese Brumma, Thomas Büttner, Dirk Roggenbuck, Elena Csernok (Senftenberg, Germany)

P56  Autoantibody detection in bullous pemphigoid: comparison of sensitivity and specificity of different diagnostic techniques
Jan Damoiseaux, Margit van Rijssingen, Nicole Warnemünde, Comelia Dähnrichs, Jan Willem Cohen Tervaert, Kai Fechner, Pamela Poblete-Gutierrez (Maastricht, The Netherlands)

P57  Detection of conformation-specific auto-antibodies to transglutaminase 6 in neurology patients
P. Aeschlimann, M. Hadjiavassiliou, Martin Hils, J. Weber, R. Pasternack, M. Adamczyk, K. Beck and D. Aeschlimann (Darmstadt, Germany)

P58  New sensitive and reliable Lateral Flow Assays for the detection of Proteinase 3 and Myeloperoxidase antibodies
J. Schulte-Pelkum, R. Lucassen, M. Petschinka, M. Fooke (Neuss, Germany)
P59 Development of anti-type VII collagen ELISA for the diagnosis and monitoring the disease activity of epidermolysis bullosa acquisita patients
Akihiro Murakami (Nagoya, Japan)

P60 Development of ELISA to detect anti-aminoacyl-tRNA synthetase autoantibodies for the diagnosis of myositis and interstitial pneumonia
Akihiro Murakami (Nagoya, Japan)

P61 Multiparametric detection of anti-ganglioside antibodies by 5 commercial immunoassays in patients with well-characterized immune-mediated peripheral neuropathies
Christiane Caudie, Arnaud Quittard-Pinon, Françoise Bouhour, Christophe Vial, Nicole Fabien (Lyon, France)

P62 Detection of autoantibodies in pemphigus, bullous pemphigoid, and epidermolysis bullosa acquisita by indirect immunofluorescence with a Biochip™ mosaic
Christian Probst, Inga-Madeleine Blöcker, Winfried Stöcker, Enno Schmidt, Detlef Zillikens, Lars Komorowski (Lübeck, Germany)

P63 Improvement in routine laboratory protocols for Systemic Sclerosis
Milvia Lotzniker, S. Finazzi, G. Re, S. Forlani, P. Faggioli (Legnano, Italy)

P64 Validation of a single multiparameter lineblot for the detection of systemic sclerosis-associated autoantibodies
Carolien Bonroy, Jens Van Praet, Vanessa Smith, Katleen Van Steendam, Tsuneyo Mimori, Ellen Deschepper, Dieter Deforce, Katrien Devreese, Filip De Keyser (Ghent, Belgium)
The modern Lecture Hall Centre of the Technical University of Dresden is located on the University Campus in the South of the city, about 15 minutes walk away from the Central Railway Station.

Address of the congress venue:
Hörsaalzentrum der Technischen Universität Dresden
Bergstrasse 64
01069 Dresden

Phone/Fax on site
Phone +49 351 463 48810 and +49 160 98 35 87 47
Fax +49 351 463 48814

Chairman
Karsten Conrad, Germany

Co-Chairmen
Edward K.L. Chan, USA
Marvin J. Fritzler, Canada
René-Louis Humbel, Luxembourg
Pier Luigi Meroni, Italy
Yehuda Shoenfeld, Israel

International Advisory Board
Luis E.C. Andrade, Brazil
Dimitrios P. Bogdanos, UK
Elena Csernok, Germany
Martin Herrmann, Germany
Falk Hiepe, Germany
Arno Kromminga, Germany
Michael Mahler, USA
Günter Steiner, Austria
Allan Wiik, Denmark
Peter Zipfel, Germany

National Organizing Committee
Rico Hiemann
Thorsten Krieger
Robert Lange
Ulrich Sack
Werner Schößler
(Members of the Advisory Committee of the GFID e.V.)

Language
English, no simultaneous translation
Silke Zwjatkovn
GFID e.V.
Veilchenweg 28
D-01326 Dresden
Phone  +49 351 26 32 279
Fax    +49 351 26 32 280
e-mail: kontakt@gfid-ev.de and gfiv.ev@me.com

<table>
<thead>
<tr>
<th>Participants</th>
<th>EUR 420</th>
</tr>
</thead>
<tbody>
<tr>
<td>GFID member</td>
<td>EUR 390</td>
</tr>
<tr>
<td>Students/Residents</td>
<td>EUR 220</td>
</tr>
<tr>
<td>One day ticket</td>
<td>EUR 140</td>
</tr>
</tbody>
</table>

(includes unlimited access to all scientific sessions, welcome reception, industrial exhibition, one copy of the Conference book and one copy of the book "Autoantibodies in Organ Specific Autoimmune Diseases – A Diagnostic Reference"

Members of the Dresden University are free of charge.

Welcome reception in the Lecture Hall Center of the Technical University of Dresden

Guided visit and Social Dinner in the Fortress of Königstein (90 €)
The Königstein Fortress (www.festung-koenigstein.de), located in the beautiful Saxon Switzerland about 40 km South-East from Dresden on the river Elbe, is one of Europe’s architecturally and historically most unique mountain fortresses. It is a unique monument to the art of European fortress construction. Its 750 years' history have made it an impressive configuration of late Gothic, Renaissance, Baroque and 19th century architecture.

15.30 Departure by bus starting from the congress venue
16.30 Guided visit of the Königstein Fortress (sturdy shoes recommended)
18.00 Social Dinner (no formal dresscode)
The following companies participate in the industrial exhibition and/or have made a generous sponsoring (in alphabetical order):

**AID Autoimmun Diagnostika GmbH** (Straßberg, Germany)
www.aid-diagnostika.com

**A. Menarini Diagnostics Deutschland. Division der BERLIN-CHEMIE AG** (Berlin, Germany)
www.menarini.com

**Aesku.Diagnostics GmbH & Co. KG**
(Wendelsheim, Germany)
www.aeskulab.com

**Beckman Coulter GmbH** (Krefeld, Germany)
www.beckmancoulter.com

**Bio-Rad Laboratories, Inc.** (Hercules, USA)
www.bio-rad.com

**BioSystems S.A.** (Barcelona, Spain)
www.biosystems.com

**Bühlmann Laboratories** (Schönenbuch, Switzerland)
www.buhlmannlabs.ch

**CellTrend GmbH** (Luckenwalde, Germany)
www.celltrend.de

**Diarect AG** (Freiburg, Germany)
www.diarect.com

**DiagnostikNet-BB e.V.** (Hennigsdorf, Germany)
www.diagnostiknet-bb.de

**DLD Diagnostika GmbH** (Hamburg, Germany)
www.dld-diagnostika.de

**Dr. Fooke Laboratorien GmbH** (Neuss, Germany)
www.fooke-labs.de
D-tek s.a. (Mons, Belgium)
www.d-tek.de

EUROIMMUN Medizinische Labordiagnostika AG
(Lübeck, Germany)
www.euroimmun.de

GA Generic Assays GmbH (Dahlewitz, Germany)
www.genericassays.com

GTI DIAGNOSTICS GmbH (Aachen/Aix la Chapelle, Germany)
www.gen-probe.com

hospital Laborverbund Brandenburg Berlin GmbH
(Bernau, Germany)
www.hospital-laborverbund.de

Immanuel Diakonie GmbH (Berlin, Germany)
www.immanuel.de/einrichtungen/immanuel-diakonie-gmbh

INOVA Diagnostics, Inc. (San Diego, USA)
www.inovadx.com

LIMETEC Biotechnologies GmbH (Bernau, Germany)
www.limetec-biotechnologies.de

Medical and Biological Laboratories Co., Ltd.
(Nagoya, Japan)
www.mbl.co.jp

Medipan GmbH (Dahlewitz, Germany)
www.medipan.de

Mikrogen GmbH (Neuried, Germany)
www.mikrogen.de

ORGENTEC Diagnostika GmbH (Mainz, Germany)
www.orgentec.com

Phadia GmbH
(now Thermo Fisher Scientific, Freiburg, Germany)
www.thermoscientific.com/phadia/de
EXHIBITORS AND SPONSORS

Seramun Diagnostica GmbH (Heidesee, Germany)
www.seramun.com

Viramed Biotech AG (Plenegg, Germany)
www.viramed.de

Vita Diagnostika GmbH, Division of EuroDiagnostica AB
(Merzhausen, Germany)
www.eurodiagnostica.com

Zedira GmbH (Darmstadt, Germany)
www.zedira.com

We thank these companies for helping to make this symposium successful.

WE HOPE TO SEE YOU NEXT TIME:

8. Immundiagnostisches Meeting, Essen (Germany) March 15-17, 2012

9. Immundiagnostisches Meeting, Dresden (Germany) March 15-17, 2013

11th Dresden Symposium on Autoantibodies, Dresden (Germany) September 01-04, 2013

www.gfid-ev.de
DiagnostikNet|BB is a high-performance network of diagnostics providers, device manufactures, leading research institutes, clinics, and medical laboratories in the Berlin-Brandenburg region. The network covers the complete value chain of in-vitro diagnostics. For this reason, we are able to offer you a broad range of services and products for medical diagnostics and research: sample delivery and biobanking, biomarker development and validation, platform-independent assay development, manufacturing of diagnostic devices, software solution support, bioinformatics and data management as well as order analysis in clinical chemistry and molecular diagnostics. Benefiting most from the network capabilities are its customers, who can be sure they receive innovative and reliable diagnostic solutions from one hand.

You profit from:

- the combination of expertise of our network members
- the close cooperation with our clinical partners and the resulting user-oriented products
- our access to new technologies at research institutes and universities in our network
- flexible and short decision making processes allowing us to implement these solutions quickly and efficiently

Contact:

Dr. Frauke Adams | Network Management
DiagnostikNet-BB | Netzwerk Diagnostik Berlin-Brandenburg e.V.
Neuendorfstr. 17 | 16761 Hennigsdorf | Germany
P +49 (0) 3302 55 199-14 | F +49 (0) 3302 55 199-10
f.adams@diagnostiknet-bb.de | www.diagnostiknet-bb.de
Platform technology for multiplex diagnostics using digital multicolor immunofluorescence

www.aklides.de